Nemonapride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328508

CAS#: 93664-94-9

Description: Nemonapride, also known as YM-09151-2 and Emilace, is a dopamine D2/D3/D4 receptor antagonist for the treatment of schizophrenia.

Chemical Structure

img
Nemonapride
CAS# 93664-94-9
Instruction

Theoretical Analysis

MedKoo Cat#: 328508
Name: Nemonapride
CAS#: 93664-94-9
Chemical Formula: C21H26ClN3O2
Exact Mass: 387.17
Molecular Weight: 387.908
Elemental Analysis: C, 65.02; H, 6.76; Cl, 9.14; N, 10.83; O, 8.25

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Nemonapride; YM-09151-2; YM091512; YM 09151 2; Emilace

IUPAC/Chemical Name: N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide

InChi Key: KRVOJOCLBAAKSJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)

SMILES Code: O=C(NC1C(C)N(CC2=CC=CC=C2)CC1)C3=CC(Cl)=C(NC)C=C3OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 387.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Assié MB, Consul-Denjean N, Koek W, Newman-Tancredi A. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology. 2005 Oct;75(2):63-8. Epub 2005 Jul 11. PubMed PMID: 16020947.

2: Noda-Saita K, Matsumoto M, Hidaka K, Hatanaka K, Ohmori J, Okada M, Yamaguchi T. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex. Biochem Biophys Res Commun. 1999 Feb 16;255(2):367-70. PubMed PMID: 10049714.

3: Prinssen EP, Kleven MS, Koek W. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties. Eur J Pharmacol. 1998 Sep 4;356(2-3):189-92. PubMed PMID: 9774248.

4: Helmeste DM, Tang SW, Li M, Fang H. Multiple [3H]-nemonapride binding sites in calf brain. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jul;356(1):17-21. PubMed PMID: 9228185.

5: Nagasaki T, Ohkubo T, Sugawar K, Yasui N, Ohtani K, Kaneko S. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):293-8. PubMed PMID: 9766869.

6: Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W Jr, Potkin S, Jones EG. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains. Brain Res. 1997 Aug 8;765(1):7-12. PubMed PMID: 9310388.

7: Kuribara H. Effects of sulpiride and nemonapride, benzamide derivatives having distinct potencies of antagonistic action on dopamine D2 receptors, on sensitization to methamphetamine in mice. J Pharm Pharmacol. 1996 Mar;48(3):292-6. PubMed PMID: 8737056.

8: Kondo T, Ishida M, Tokinaga N, Mihara K, Yasui-Furukori N, Ono S, Kaneko S. Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):287-91. PubMed PMID: 11817505.

9: Assié MB, Cosi C, Koek W. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol. 1997 Sep 10;334(2-3):141-7. PubMed PMID: 9369342.

10: Kondo T, Mihara K, Yasui N, Nagashima U, Ono S, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Otani K. Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. J Clin Psychopharmacol. 2000 Aug;20(4):404-9. PubMed PMID: 10917400.